Verteporfin ocular photodynamic therapy.
This article reviews the pharmacotherapeutics of verteporfin (Visudyne), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials with verteporfin to treat subfoveal choroidal neovascularisation in age-related macular degeneration, ocular histoplasmosis syndrome and pathologic myopia. In addition, the safety profile and side effects of verteporfin are discussed.
Bakri
Sophie J
SJ
Cole Eye Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Kaiser
Peter K
PK
D020256:Choroidal Neovascularization / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011166:Porphyrins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin